A Delaware federal judge has upheld a jury’s decision that AstraZeneca owes $107.5 million in royalty damages for infringing patents related to Pfizer’s cancer treatment. On Tuesday, the court rejected AstraZeneca’s claims that the patents in question were unenforceable and that the asserted claims were invalid. This ruling solidifies the jury’s determination and requires AstraZeneca to make the substantial payment. For more detailed information, refer to the original article here.